Escala Medical Secures $45M to Revolutionize Pelvic Organ Prolapse Treatment

A New Era in Women’s Health Innovation Begins with Mendit

In a world where medical advancements often overlook the specific needs of women, Escala Medical is making waves by addressing a critical health issue—Pelvic Organ Prolapse (POP)—with a game-changing, minimally invasive solution. The Israeli-based medtech startup has just raised \$4.5 million in a Series A round, marking a significant leap in its mission to offer safer, more accessible alternatives to invasive pelvic repair surgeries. Co-financed by the European Innovation Council (EIC) Fund, this funding also follows a previous €2.5 million grant awarded through the EIC Accelerator program in October 2023. With this, Escala’s total funding now surpasses \$8 million.

Founded in 2014 by two leading pelvic surgeons, Dr. Roger Goldberg and Prof. Douglas Scherr, the company has developed Mendit, a minimally invasive, office-based device to treat POP. Traditional surgical methods for POP are often invasive, come with high recovery times, and are generally unsuitable for a large portion of the patient population—nearly 90% of the 8 million women annually seeking POP care in the U.S. and Europe never undergo surgery. Mendit offers a reversible, incision-free, anchor-based solution that’s FDA-cleared, already used in over 500 successful cases, and available in 48 U.S. hospitals with many more in the pipeline.

The new funding will allow Escala to expand its commercial footprint across the United States, Europe (post-CE mark approval expected by 2026), and Southeast Asia, with a new Singapore-based distribution partnership already signed. The capital will also support product improvements, post-market clinical research, and development of next-generation devices. With key support from global backers like The Trendlines Group and the Consensus Business Group (CBG), the company is now set to become a leader in the rapidly growing, \$7 billion POP treatment market.

What Undercode Say:

Escala Medical’s latest milestone goes beyond just a financial win—it signals a paradigm shift in how women’s pelvic health is approached in modern medicine. POP has historically been underserved and stigmatized, despite its prevalence. Escala disrupts this space by replacing outdated surgical interventions with precision-engineered technology that empowers patients and clinicians alike.

What stands out is Escala’s ability to tap into multiple growth levers simultaneously:

Regulatory traction: Achieving FDA clearance and rapid hospital adoption in under a year is no small feat. It suggests both strong clinical validation and urgent demand.
Market fit: With 90% of symptomatic women avoiding surgery, Mendit’s non-surgical model removes key adoption barriers—cost, fear, and recovery time.
Global strategy: Rather than stagnate in one market, Escala is aligning with regional distribution partners to penetrate SEA, EU, and the U.S.—a highly strategic move for scalability.
Clinical leadership: With founders who are both pelvic surgeons, there’s deep user empathy baked into the product. This isn’t just tech for the sake of it—it’s clinically intuitive and surgically precise.

Another layer of Escala’s success is its dual-track funding from the EIC—a grant and an equity stake—which reflects rare institutional confidence. The fact that both public and private investors are rallying behind this cause suggests that women’s health is finally being recognized as a high-growth, high-impact vertical in medtech.

However, challenges remain. CE mark approval is still pending, and Europe’s regulatory hurdles can delay market entry. Moreover, competition from firms like EnPlace or AnchorSure—despite being more invasive—still exists. Escala must now shift from a promising innovator to an operationally flawless scaler. This means handling logistics, training clinicians across borders, and managing quality assurance at scale.

If successful, Escala won’t just be another medtech company—it will be a case study in how to commercialize socially meaningful innovation without compromising on growth. It’s not just about fixing anatomy; it’s about rewriting how women experience healthcare.

🔍 Fact Checker Results:

✅ Mendit received FDA clearance in April 2023 and was commercially launched later that year.
✅ The POP treatment market is estimated at over \$7 billion globally.
✅ Escala’s Mendit has already been used in more than 500 successful procedures.

📊 Prediction:

With regulatory progress in full swing and funding secured, Escala is likely to become a dominant player in pelvic care by 2027, especially if CE mark approval is achieved by 2026 as anticipated. Expect wider adoption across Asia and private European clinics, alongside potential licensing or acquisition interest from major medtech firms like Medtronic or Boston Scientific. If clinical outcomes remain favorable, Escala could even pursue an IPO by 2028 or earlier, positioning itself as a women’s health unicorn in the making.